Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: The molecular and clinical features of KRAS-mutated lung cancer patients treated with immunotherapy have yet to be well characterized, and little information is known about resistance in these patients. The goal of this study is to better understand the survival results of KRAS-mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Dan, Li, Haiqing, Mambetsariev, Isa, Mirzapoiazova, Tamara, Chen, Chen, Fricke, Jeremy, Kulkarni, Prakash, Villaflor, Victoria, Arvanitis, Leonidas, Hamilton, Stanley, Afkhami, Michelle, Pillai, Raju, Armstrong, Brian, Erhunmwunsee, Loretta, Massarelli, Erminia, Sattler, Martin, Amini, Arya, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562655/
https://www.ncbi.nlm.nih.gov/pubmed/36230855
http://dx.doi.org/10.3390/cancers14194933

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562655/
https://www.ncbi.nlm.nih.gov/pubmed/36230855
http://dx.doi.org/10.3390/cancers14194933

Ejemplares similares